Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · July 10, 2023

Plasma cfDNA PIK3CA and TP53 Mutations Predicted Inferior Endocrine-Based Treatment Outcomes in Patients With ER+ Metastatic Breast Cancer

Breast Cancer Research and Treatment


Additional Info

Disclosure statements are available on the authors' profiles:

Breast Cancer Research and Treatment
Plasma cell-free tumor DNA, PIK3CA and TP53 mutations predicted inferior endocrine-based treatment outcome in endocrine receptor-positive metastatic breast cancer
Breast Cancer Res Treat 2023 Jun 21;[EPub Ahead of Print], TW Chen, W Hsiao, MS Dai, CH Lin, DY Chang, IC Chen, MY Wang, SH Chang, SM Huang, AL Cheng, KW Wu, KT Tan, YS Lu

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading